Rapporter om forskellige maligniteter (inkl. bryst - og lungecarcinom og lymfom), er blevet modtaget i postmarketingperioden (se afsnit 4. 4).
Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been received in the postmarketing period (see section 4.4).